Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genome-wide screening of genetic structureand differentially selected regions amongLandrace, Erhualianand Meishanpig using SLAF-seq technology

ABSTRACT: Genome-wide screening of genetic structureand differentially selected regions amongLandrace, Erhualianand Meishanpig using SLAF-seq technology

PROVIDER: PRJNA345157 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR4358050_1.fastq.gz	Fastqsanger.gz
	SRR4358050_2.fastq.gz	Fastqsanger.gz
	SRR4358080_1.fastq.gz	Fastqsanger.gz
	SRR4358080_2.fastq.gz	Fastqsanger.gz
	SRR4358670_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 162

Similar Datasets

Sequencing of candidate positively-selected regions in the human genome

Project description:Sequencing of candidate positively-selected regions in the human genome

| PRJEB2148 | ENA

Validation of differentially methylated DNA regions in colorectal precancerous lesions.

Project description:In this study, we validated 992 previously identified differentially methylated regions (DMRs) in colorectal precancerous lesions compared to adjacent normal mucosa in a new series of 59 prospectively collected lesions and matched normal tissue using targeted bisulfite sequencing. Strong differences in methylation level were observed across the full set of validated DMRs. Based on the mean methylation levels of a panel of 30 selected DMRs tumors could be accurately classified. We thus provide a large list of validated DNA markers to be exploited in the development of noninvasive, colorectal tumor screening assays.

2023-03-30 | E-MTAB-12612 | biostudies-arrayexpress

The influence of initial screening test technology on participation in rescreening for colorectal cancer

Project description:Interventions: The aim is to determine the effect of the type of test offered in a first round of a screening program for colorectal cancer on participation in a second round. Group 1: First round of screening Hemoccult II Sensa, low technology test. Second round of screening: InSure test, high technology. Group 2: First round of screening: FlexSure OBT, mid technology test. Second round: InSure OBT, high technology. Group 3: First round of screening: InSure OBT, high technology test. Second round: InSure OBT, high technology. Primary outcome(s): Paricipation in screening defined as return of a screening kit 12 weeks from offer.[] Study Design: Purpose: Prevention; Allocation: Randomised controlled trial; Masking: Blinded (masking used);Assignment: Parallel;Type of endpoint: Efficacy

| 2452279 | ecrin-mdr-crc

Homo sapiens

Project description:screening for pre-selected regions within BRCA1 and BRCA2

| PRJNA510905 | ENA

methylCC: technology-independent estimation of cell type composition using differentially methylated regions.

Project description:A major challenge in the analysis of DNA methylation (DNAm) data is variability introduced from intra-sample cellular heterogeneity, such as whole blood which is a convolution of DNAm profiles across a unique cell type. When this source of variability is confounded with an outcome of interest, if unaccounted for, false positives ensue. Current methods to estimate the cell type proportions in whole blood DNAm samples are only appropriate for one technology and lead to technology-specific biases if applied to data generated from other technologies. Here, we propose the technology-independent alternative: methylCC, which is available at https://github.com/stephaniehicks/methylCC.

| S-EPMC6883691 | biostudies-literature

Development of MDM2-targeting PROTAC technology for advancing bone regeneration

Project description:MDM2 inhibitor remarkably induced biomineralization in hDPSCs but it remained the problem that p53 activation is insufficient due to MDM2-p53 autoregulatory feedback loop. To overcome the limitation of the MDM2 inhibitors, we applied proteolysis targeting chimera (PROTAC), a technology that degrades a protein of interest (POI) by intracellular ubiquitin-proteasome system. Hence, we propose a strategy to induce hard tissue regeneration by MDM2-targeting PROTAC technology. We selected Nutlin-3 of POI ligand among various MDM2 inhibitors based on the screening process, and the selected CRBN of E3 ligase ligand. The MDM2-PROTAC synthesis platform was designed by each ligand combination. By performing the degradation test for selected compounds, we evaluated the characteristics of the developed MDM2 PROTAC such as the maximal degradation concentration (DCmax), the half of maximal degradation concentration (DC50), and half-lifetime. To investigate gene expression profiling of MDM2-targeting small molecules, we conducted RNA-sequencing under MDM2 PROTAC and Nutlin-3 (POI ligand) treated conditions. We not only confirmed a robust effect on biomineralization by MDM2-targeting small molecules but also demonstrated the potent osteogenic differentiation ability of MDM2 PROTAC when compared to an MDM2 inhibitor. MDM2-PROTAC significantly increased mRNA levels of osteogenic differentiation marker genes. Also, the significant bone generation effect of MDM2 PROTAC was validated in an ovariectomy (OVX)-induced osteoporosis animal model. Through these results, it is expected that a new therapeutic modality for hard tissue regeneration will be possible, and the application range of the PROTAC system can be expanded.

2024-06-11 | GSE255297 | GEO

Methylation analysis of promoter regions for selected tumour suppressor genes in DNA from white blood cells.

Project description:Methylation analysis of promoter regions for selected tumour suppressor genes in DNA from white blood cells.

| PRJNA832682 | ENA

Mutational screening of linkage assay-identified candidate regions in familial breast cancer

Project description:Background: The classical candidate-gene approach has failed to identify novel breast cancer susceptibility genes. Nowadays, massive parallel sequencing technology allows the development of studies unaffordable a few years ago. However, analysis protocols are not yet sufficiently developed to extract all information from the huge amount of data obtained. Methodology/Principal Findings: In this study, we performed high throughput sequencing in two regions located on chromosomes 3 and 6, recently identified by linkage studies by our group as candidate regions for harbouring breast cancer susceptibility genes. In order to enrich for the coding regions of all described genes located in both candidate regions, a hybrid-selection method on tiling microarrays was performed. Conclusions/Significance: We developed an analysis pipeline based on SOAP aligner to identify candidate variants with a high real positive confirmation rate (0.89), with which we identified eight variants considered candidates for functional studies. The results suggest that the present strategy is a valid second step for identifying high penetrance genes. 20 Samples / 4 Pooled Controls

2011-02-18 | E-GEOD-20406 | biostudies-arrayexpress

Chemotherapy selected 4T1 cells

Project description:Chemotherapy selected 4T1 cells

| PRJNA892046 | ENA

Mutational screening of linkage assay-identified candidate regions in familial breast cancer

2011-02-18 | GSE20406 | GEO